Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells-Reference-Cited by-同舟云学术

Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells

Published:2022-01 Issue: Volume:55 Page:101410
ISSN:2212-8778
Container-title:Molecular Metabolism
language:en
Short-container-title:Molecular Metabolism

Author:

Trinh Anne,Khamari Raeeka,Fovez Quentin^ORCID,Mahon François-Xavier,Turcq Béatrice,Bouscary Didier,Maboudou Patrice,Joncquel Marie,Coiteux Valérie,Germain Nicolas^ORCID,Laine William,Dekiouk Salim,Jean-Pierre Sandrine,Maguer-Satta Veronique,Ghesquiere Bart,Idziorek Thierry,Quesnel Bruno^ORCID,Kluza Jerome^ORCID,Marchetti Philippe^ORCID

Funder

Ligue Nationale Contre Le Cancer

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference40 articles.

1. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease;Rousselot;Journal of Clinical Oncology,2014

2. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity;Corbin;Journal of Clinical Investigation,2011

3. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group;Rea,2018

4. Why doesn't imatinib cure chronic myeloid leukemia?;Redner;The Oncologist,2010

5. When to Stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia;Laneuville;Current Treatment Options in Oncology,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors;Experimental Hematology;2024-09

2. Glutamine-addiction in cisplatin resistant cancer cells is mediated by SLC7A11 and can be targeted with asparaginase therapy;2024-07-22

3. Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia;Frontiers in Oncology;2023-02-01

4. Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity;Blood;2023-01-12

5. Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review;Frontiers in Oncology;2022-12-06